- Case report
- Open Access
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
© Orditura et al; licensee BioMed Central Ltd. 2007
Received: 14 November 2006
Accepted: 22 April 2007
Published: 22 April 2007
Hepatoid adenocarcinoma (HAC) is a peculiar type of extrahepatic adenocarcinoma generally characterized by adenocarcinomatous and hepatocellular carcinoma (HCC)-like foci. Stomach is the most frequent site where hepatoid adenocarcinoma occurs, although it has been described in many other organs. On the other side, liposarcoma is a rare, malignant tumor that develops from fat cells.
We describe here a case of hepatoid carcinoma in collision with a liposarcoma of the left colon serosa in a 71-year-old man. It presented as an abdominal mass involving several organs, falsely mimicking metastatic colonic adenocarcinoma. Recognition of this entity was evident on microscopic evaluation following surgery. The patient had an objective response following liposomal antracycline chemotherapy, with a 3-year overall survival.
To our knowledge, this is the first case of a hepatoid tumor colliding with a liposarcoma of the left colon serosa reported to date.
Hepatoid adenocarcinoma (HAC) is a type of extrahepatic adenocarcinoma, which shows a striking morphologic similarity to hepatocellular carcinoma. It is generally characterized by adenocarcinomatous and hepatocellular carcinoma (HCC)-like foci. This variant of adenocarcinoma has been demonstrated to be an alpha-fetoprotein (AFP)-producing carcinoma arising in extra hepatic organs, and it mimics hepatocellular carcinoma in morphological and functional terms.
In most instances, hepatoid carcinoma has been found in the stomach [1, 2], but it also occurs in many other organs. Recently, HAC occurrence has been reported in such organs as ileum, gallbladder , ovary [4, 5], pancreas [6, 7], lung [8, 9], renal pelvis , uterus , and urinary bladder .
A prompt and accurate diagnosis of hepatoid adenocarcinoma is important because prognosis is very poor compared with that of both common types of adenocarcinoma  and AFP-producing adenocarcinomas .
Liposarcoma is a rare, malignant tumor that develops from fat cells. It is the most common soft tissue sarcoma and accounts for 20% of all malignant mesenchymal tumors. This tumor typically appears in the deep fat tissues of the thigh or abdomen in people aged 50 to 70. Prognosis varies depending on site of origin, type of cancer cell, tumor size, depth, and proximity to lymph nodes. Metastases are common and the 5-year survival rate for a deep and high-grade liposarcoma is less than 50%. This paper describes the unusual occurrence of a hepatoid carcinoma colliding with a liposarcoma.
A 71-year-old man was admitted because of abdominal pain in January 2003. His past medical history was significant for a monoclonal gammopathy and surgery for hip prosthesis 2 years before the current admission. At another hospital an abdominal computed tomography (CT) scan had revealed a left-sided mass (10 × 9 cm) involving the diaphragm, spleen, and, from the outside, the left colon flexure. Tumor marker (CEA and CA19-9) serum levels were normal, with the exception of serum AFP, which was markedly elevated (44074.6 ng/ml). However, no CT evidence of primary hepatocellular carcinoma was found. Endoscopy of the upper and lower gastrointestinal tract did not show any primary tumor. A FNAB was performed and cytologic analysis was consistent with a moderately differentiated adenocarcinoma.
Since surgery was deemed not to be feasible, 5-fluorouracil and oxaliplatin-based chemotherapy was administered for a total of 6 cycles, resulting in stable disease.
Finally, a collision zone between the two tumors was identified, consisting of a large area infiltrated by islets or layers of AFP-positive, acidophilic, polygonal cells in contiguity and continuity with islets of lipoblast-rich fat tissue (well-differentiated liposarcoma).
The serum AFP level decreased after surgery (9000 ng/ml). The patient received first line chemotherapy with liposomal doxorubicin for 8 cycles resulting in disease control for 2 years. The patient then had hepatic metastases and died 3 years after the first diagnosis.
The unusual presentation of two entirely different primary malignancies in close proximity to each other is defined as a "collision tumor". To our knowledge, this is the first case of a hepatoid tumor colliding with a liposarcoma of the left colon serosa reported to date. This collision tumor presented as an abdominal mass with extensive involvement of abdominal organs, thus falsely mimicking metastatic dedifferentiated colonic adenocarcinoma. In the absence of a primary identifiable liver disease, this was consistent with a hepatoid carcinoma arising from the peritoneum. The dual nature of the mass was revealed on histologic analysis; it has to be stressed that the two tumors collided at a clear boundary with no evidence of transition both grossly and microscopically; in addition, the immunohistochemical staining pattern for AFP was quite different between the two tumors [[2, 9] 15]. In cases such this one, it would be interesting to find out whether these are true collision tumors or single neoplasms with divergent differentiation. However, this was beyond the scope of this report in our case because of the need of complex molecular analyses. Finally, it is uncommon for a liposarcoma to respond to antracycline-based chemotherapy, given its chemo-resistance. A further peculiarity of this case was the unusual presentation of the hepatoid carcinoma, which showed itself as an abdominal extracolonic mass, whereas in other reported cases it would arise in such definite organs as the ovary, the lung or the bladder.
To data, this is the first case of hepatoid carcinoma colliding with a liposarcoma of the left colon serosa. The unusually good response of this tumor to chemotherapy is worth reporting, especially because systemic chemotherapy is considered little or non effective. Although this is a single case report, patient's response shows that liposomial antracycline therapy is possible for this type of tumor.
The written consent of the patient was obtained for publication of this case report.
- Ishikura H, Fukasawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M: An AFP – producing gastric carcinoma with features of hepatic differentiation: case report. Cancer. 1985, 56: 840-843. 10.1002/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Kishimoto T, Nagai Y, Kato K, Ozaki D, Ishikura H: Hepatoid adenocarcinoma: a new clinicopathological entity and the hypotheses on carcinogenesis. Med Electron Microsc. 2000, 33: 57-63. 10.1007/s007950070002.View ArticlePubMedGoogle Scholar
- Nakashima H, Nagafuchi K, Satoh H, Takeda K, Yamasaki T, Yonemasu H, Kishikawa H: Hepatoid adenocarcinoma of the gallbladder. J Hepatobiliary Pancreat Surg. 2000, 7: 226-230. 10.1007/s005340050181.View ArticlePubMedGoogle Scholar
- Ishikura H, Scully RE: Hepatoid carcinoma of the ovary: A newly described tumor. Cancer. 1987, 60: 2775-2784. 10.1002/1097-0142(19871201)60:11<2775::AID-CNCR2820601130>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Matsuta M, Ishikura H, Murakami K, Kagabu T, Nishiya I: Hepatoid carcinoma of the ovary: a case report. Int J Gynecol Pathol. 1991, 10: 302-310.View ArticlePubMedGoogle Scholar
- Paner GP, Thompson KS, Reyes CV: Hepatoid carcinoma of the pancreas. Cancer. 2000, 88: 1582-1589. 10.1002/(SICI)1097-0142(20000401)88:7<1582::AID-CNCR12>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
- Yano T, Ishikura H, Wada T, Kishimoto T, Kondo S, Katoh H, Yoshiki T: Hepatoid adenocarcinoma of the pancreas. Histopahtology. 1999, 35: 90-92. 10.1046/j.1365-2559.1999.0728f.x.View ArticleGoogle Scholar
- Ishikura H, Kanda M, Ito M, Nosaka K, Mizuno K: Hepatoid adenocarcinoma: a distinctivehistological subtype of alphafetoprotein-producing lung carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990, 417: 73-80. 10.1007/BF01600112.View ArticlePubMedGoogle Scholar
- Arnould L, Drouot F, Fargeot P, Bernard A, Foucher P, Collin F, Petrella T: Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha fetoprotein producing lung tumor. Am J Surg Pathol. 1997, 21: 1113-1118. 10.1097/00000478-199709000-00018.View ArticlePubMedGoogle Scholar
- Ishikura H, Ishiguro T, Enatsu C, Fujii H, Kakuta Y, Kanda M, Yoshiki T: Hepatoid adenocarcinoma of the renal pelvis producing alpha-fetoprotein of hepatic type and bile pigment. Cancer. 1991, 67: 3051-3056. 10.1002/1097-0142(19910615)67:12<3051::AID-CNCR2820671220>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Yamamoto R, Ishikura H, Azuma M, Hareyama H, Makinoda S, Koyama Y, Nishi S, Fuijmoto S: Alpha-fetoprotein production by a hepatoid adenocarcinoma of the uterus. J Cli Pathol. 1996, 49: 420-422.View ArticleGoogle Scholar
- Sinard J, Macleay L, Melamed J: Hepatoid adenocarcinoma in the urinary bladder: Unusual localization of a newly recognized tumor type. Cancer. 1994, 73: 1919-1925. 10.1002/1097-0142(19940401)73:7<1919::AID-CNCR2820730724>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Nagai E, Ueyama T, Yao T, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: A clinicopathologic and immunohistochemical analysis. Cancer. 1993, 72: 1827-1835. 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Motoyama T, Aizawa K, Watanabe H, Fukase M, Sito K: alfa-Fetoprotein producing gastric carcinomas: a comparative study of three different subtypes. Acta Pathol Jpn. 1993, 43: 654-661.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.